Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in NTLA.
← Back to Free Index

NTLA

Analysis as of: 2026-10-14
Intellia Therapeutics, Inc.
Intellia develops in vivo gene-editing therapies for hereditary angioedema, transthyretin amyloidosis and other severe diseases.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approval Could Unlock a Rare-Disease Editing Franchise
A successful lonvo-z launch could turn this from a collaboration-funded science story into a real commercial gene-editing company. The upside is meaningful, but it still depends on clearing a narrow regulatory and launch path.

Analysis

Thesis
If lonvo-z converts its March 10, 2027 FDA date into a clean launch, Intellia can step from collaboration-funded R&D into an owned rare-disease gene-editing franchise; that business-model shift, plus partial nex-z recovery and selective licensing, supports a credible multi-year rerating.
Last Economy Alignment
AI lowers discovery and analysis costs, but Intellia's scarce assets are FDA permissioning, human safety data, IP and commercialization rights. That is a real positive, but biology and regulation still cap the flywheel.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.7x (from 5 most recent analyses)
Reasoning
This is mainly a business-model transition story. Today the company is valued on optionality and collaboration revenue; by 2031 it can plausibly be valued on owned product sales if lonvo-z launches well. I underwrite meaningful HAE revenue, some ATTR contribution, and modest licensing, but I do not give credit for a broad platform mania because approval, payer conversion and second-asset validation still matter too much.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The setup is attractive because one approval can change the business model quickly, but the path is narrow. The key risks are a negative or label-limiting lonvo-z review, slower-than-expected payer or physician adoption of a one-time HAE therapy, nex-z failing to regain enough safety credibility to become a second value engine, and launch-era cash use constraining flexibility before the franchise fully proves itself.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.32
They own a hard-to-copy drug package and human safety data that generic AI cannot replace, so cheaper AI mostly helps them work faster rather than making them obsolete. The catch is that biology and the FDA still control the clock, which keeps the upside real but gated.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$23.11
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case